Department of Cardiology, Kishiwada Tokushukai Hospital, Kishiwada City, Osaka, Japan.
Catheter Cardiovasc Interv. 2013 Nov 1;82(5):696-700. doi: 10.1002/ccd.24916. Epub 2013 Apr 8.
To evaluate initial and long-term results of endovascular therapy (EVT) for symptomatic subclavian artery (SCA) disease.
EVT for SCA disease has a similar success rate as open surgery, but the long-term patency of EVT alone is uncertain.
We retrospectively studied 59 consecutive patients (42 males and 17 females) with 60 lesions. Mean patient age was 68 ± 10 years. Clinical symptoms were vertebrobasilar insufficiency in 21 patients (35.0%), arm claudication in 20 patients (33.3%), angina pectoris in 12 patients (20%), severe arm ischemia in 3 patients (5.0%), vascular access insufficiency in 3 patients (5.0%), and leg ischemia in 1 patient (1.7%). A total of 57 stents were implanted. All patients were followed up at 1, 3, 6, and 12 months after the procedure and annually thereafter.
The technical success rate was 93.3%. All patients for whom technical success was obtained received stents. There were four technical failures, all of which were owing to the failure of crossing the wire in occluded lesions. There were no procedure-related deaths. There were two stroke events (3.4%) and one embolic event (1.7%). Primary patency rates were 94.9, 90.8, and 85.8% at 1, 3, and 5 years, respectively.
EVT for SCA disease is an effective treatment with regard to initial success rate, clinical efficacy, and long-term primary patency. This minimally invasive procedure is appropriate as the treatment of first choice for proximal subclavian arterial obstructive disease.
评估症状性锁骨下动脉(SCA)疾病的血管内治疗(EVT)的初始和长期结果。
SCA 疾病的 EVT 成功率与开放手术相似,但单独 EVT 的长期通畅率尚不确定。
我们回顾性研究了 59 例连续患者(42 名男性和 17 名女性)的 60 处病变。患者平均年龄为 68 ± 10 岁。临床症状包括 21 例(35.0%)椎基底动脉供血不足、20 例(33.3%)手臂跛行、12 例(20%)心绞痛、3 例(5.0%)严重手臂缺血、3 例(5.0%)血管通路不足和 1 例(1.7%)下肢缺血。共植入 57 个支架。所有患者在术后 1、3、6 和 12 个月以及此后每年进行随访。
技术成功率为 93.3%。所有获得技术成功的患者均接受了支架治疗。有 4 例技术失败,均因闭塞病变中导丝无法穿过所致。无手术相关死亡。有 2 例(3.4%)卒中事件和 1 例(1.7%)栓塞事件。1、3 和 5 年的初始通畅率分别为 94.9%、90.8%和 85.8%。
SCA 疾病的 EVT 在初始成功率、临床疗效和长期初始通畅率方面是一种有效的治疗方法。这种微创方法适合作为治疗近端锁骨下动脉阻塞性疾病的首选治疗方法。